The use of passive rabies immunotherapy: From the past to the future;L'immunothérapie antirabique passive d'hier et d'aujourd'hui

Biologie Aujourd'hui

Volumn 204, Issue 1, 2010, Pages 71-80

  Bourhy, Hervé ^a   Dacheux, Laurent ^a   Ribadeau Dumas, Florence ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

anaphylactic reactions; monoclonal antibodies; passive immunotherapy; Rabies

Indexed keywords

RABIES VACCINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; DEVELOPING COUNTRY; HISTORY; HORSE; HORSE DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METHODOLOGY; PASSIVE IMMUNIZATION; RABIES; RABIES VIRUS; VIROLOGY;

ANIMALS; DEVELOPING COUNTRIES; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HORSE DISEASES; HORSES; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION, PASSIVE; RABIES; RABIES VACCINES; RABIES VIRUS;

ANIMALIA; EQUIDAE;

EID: 78149241192     PISSN: 21050678     EISSN: 21050686     Source Type: Journal    
DOI: 10.1051/jbio/2009049     Document Type: Article

References (78)

1. Anderson D.C., WHO guidelines dealing with immunoglobulin use impede rabies prevention. Asian Biomedicine, 2007, 1, 103-107.
2. Anderson G.R., Sgouris J.T., The preparation of rabies immune globulin and use in monkeys following virus challenge, Symposia Series in Immunobiological Standardization, T. International Symposium on Rabies (Ed.), 1965, Karger, Basel, p. 319.
3. Anonymous., WHO Expert Consultation on rabies. In World Health Organ Tech Rep Ser, WHO, 2005, Geneva, pp. 1-88.
4. Archer B.G., Dierks R.E., Effects of homologous or heterologous antiserum on neutralizing-antibody response to rabies vaccine. Bull World Health Organ, 1968, 39, 407-417.
5. Atanasiu P., Bahmanyar M., Baltazard M., Fox J.P., Habel K., Kaplan M.M., Kissling R.E., Komarov A., Koprowski H., Lépine P., Perez Gallardo F., Schaeffer M., Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 1. Bull World Health Organ, 1956, 14, 593-611.
6. Atanasiu P., Bahmanyar M., Baltazard M., Fox J.P., Habel K., Kaplan M.M., Kissling R.E., Komarov A., Koprowski H., Lépine P., Perez Gallardo F., Schaeffer M., Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 2. Bull World Health Organ, 1957, 17, 911-932.
7. Atanasiu P., Cannon D.A., Dean D.J., Fox J.P., Habel K., Kaplan M.M., Kissling R.E., Koprowski H., Lépine P., Perez Gallardo F., Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 3. Bull World Health Organ, 1961, 25, 103-114.
8. Atanasiu P., Dean D.J., Habel K., Kaplan M.M., Koprowski H., Lépine P., Serie C., Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 4. Bull World Health Organ, 1967, 36, 361-365.
9. Babes V., Lepp M., Recherches sur la vaccination antirabique. Ann Inst Pasteur (Paris), 1889, 3, 385-390.
10. Babes V., Cherchez T., Expérience sur l'atténuation du virus fixe. Ann Inst Pasteur (Paris), 1891, 10, 625-632.
11. Badrane H., Bahloul C., Perrin P., Tordo N., Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol, 2001, 75, 3268-3276.
12. Bahmanyar M., Results of rabies post-exposure treatment with antirabies serum and the human diploid cell vaccine in Iran. Dev Biol Stand, 1978, 40, 163-165.
13. Bahmanyar M., Fayaz A., Nour-Salehi S., Mohammadi M., Koprowski H., Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. J Am Med Assoc, 1976, 236, 2751-2754.
14. Bahmanyar M., Fayaz A., Nour-Salehi S., Mohammadi M., Koprowski H., Successful protection of humans expo-sed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antira-bies serum. Wilderness Environ Med, 2000, 11, 42-46.
15. Bakker A.B., Marissen W.E., Kramer R.A., Rice A.B., Weldon W.C., Niezgoda M., Hanlon C.A., Thijsse S., Backus H.H., de Kruif J., Dietzschold B., Rupprecht C.E., Goudsmit J., Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol, 2005, 79, 9062-9068.
16. Bakker A.B., Python C., Kissling C.J., Pandya P., Marissen W.E., Brink M. F., Lagerwerf F., Worst S., van Corven E., Kostense S., Hartmann K., Weverling G.J., Uytdehaag F., Herzog C., Briggs D.J., Rupprecht C.E., Grimaldi R., Goudsmit J., First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine, 2008, 26, 5922-5927.
17. Baltazard M., Bahmanyar M., Field trials with rabies vaccine on persons bitten by rabid wolves. Bull World Health Organ, 1955, 13, 747-772.
18. Benmansour A., Leblois H., Coulon P., Tuffereau C., Gaudin Y., Flamand A., Lafay F., Antigenicity of rabies virus glycoprotein. J Virol, 1991, 65, 4198-4203.
19. Bourhy H., Dacheux L., Strady C., Mailles A., Rabies in Europe in 2005. Euro Surveill, 2005, 10, 213-216.
20. Bourhy H., Goudal M., Mailles A., Sadkowska-Todys M., Dacheux L., Zeller H., Is there a need for anti-rabies vaccine and immunoglobulins rationing in Europe? Euro Surveill, 2009, 14.
21. Cabasso V.J., Properties of rabies immune globulin of human origin. J Biol Stand, 1974, 2, 43-50.
22. Cabasso V.J., Dobkin M.B., Roby R.E., Hammar A.H., Antibody response to a human diploid cell rabies vaccine. Appl Microbiol, 1974, 27, 553-561.
23. Cabasso V.J., Loofbourow J.C., Roby R.E., Anuskiewicz W., Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects. Bull World Health Organ, 1971, 45, 303-315.
24. Champion J.M., Kean R.B., Rupprecht C.E., Notkins A.L., Koprowski H., Dietzschold B., Hooper D.C., The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods, 2000, 235, 81-90.
25. Coutard B., Gorbalenya A.E., Snijder E.J., Leontovich A.M., Poupon A., de Lamballerie X., Charrel R., Gould E.A., Gunther S., Norder H., Klempa B., Bourhy H., Rohayem J., L'Hermite E., Nordlund P., Stuart D.I., Owens R.J., Grimes J.M., Tucker P.A., Bolognesi M., Mattevi A., Coll M., Jones T.A., Aqvist J., Unge T., Hilgenfeld R., Bricogne G., Neyts J., La Colla P., Puerstinger G., Gonzalez J.P., Leroy E., Cambillau C., Romette J.L., Canard B., The VIZIER project: preparedness against pathogenic RNA viruses. Antiviral Res, 2008, 78, 37-46.
26. Cupo P., Azedevo-Marques M.M., Sarti W., Hering S.E., Proposal of abolition of the skin sensitivity test before equine rabies immune globulin application. Rev Inst Med Trop Sao Paulo, 2001, 43, 51-53.
27. Dacheux L., Reynes J.M., Buchy P., Sivuth O., Diop B.M., Rousset D., Rathat C., Jolly N., Dufourcq J.B., Nareth C., Diop S., Iehle C., Rajerison R., Sadorge C., Bourhy H., A reliable diagnosis of human rabies based on analysis of skin biopsy specimens. Clin Infect Dis, 2008, 47, 1410-1417.
28. de Kruif J., Bakker A.B., Marissen W.E., Kramer R.A., Throsby M., Rupprecht C.E., Goudsmit J., A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med, 2007, 58, 359-568.
29. Dean D., Local wound treatment of animal bites, Proc. Nat. Rabies Symposium, Nat. Commun. Dis. Center, 1966, Atlanta, Georgia, p. 85.
30. Dean D.J., Baer G.M., Thompson W.R., Studies on the local treatment of rabies-infected wounds. Bull World Health Organ, 1963, 28, 477-486.
31. Delmas O., Holmes E.C., Talbi C., Larrous F., Dacheux L., Bouchier C., Bourhy H., Genomic diversity and evolution of the lyssaviruses. PLoS ONE, 2008, 3, e2057.
32. Dietzschold B., Gore M., Casali P., Ueki Y., Rupprecht C.E., Notkins A.L., Koprowski H., Biological characterization of human monoclonal antibodies to rabies virus. J Virol, 1990, 64, 3087-3090.
33. Dietzschold B., Tollis M., Lafon M., Wunner W.H., Koprowski H., Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies. Virology, 1987, 161, 29-36. (Pubitemid 17161552)
34. Dodet B., Adjogoua E.V., Aguemon A.R., Amadou O.H., Atipo A.L., Baba B.A., Ada S.B., Boumandouki P., Bourhy H., Diallo M.K., Diarra L., Diop B. M., Diop S.A., Fesriry B., Gosseye S., Hassar M., Kinge T., Kombila Nzamba T.E., Yandoko E.N., Nzengue E., Ramahefalalao E.F., 2nd, Ratsitorahina M., Simpore L., Soufi A., Tejiokem M., Thiombano R., Tiembre I., Traore A.K., Wateba M.I., Fighting rabies in Africa: the Africa Rabies Expert Bureau (AfroREB). Vaccine, 2008 a, 26, 6295-6298.
35. Dodet B., Goswami A., Gunasekera A., de Guzman F., Jamali S., Montalban C., Purba W., Quiambao B., Salahuddin N., Sampath G., Tang Q., Tantawichien T., Wimalaratne O., Ziauddin A., Rabies awareness in eight Asian countries. Vaccine, 2008 b, 26, 6344-6348.
36. Dorfman N., Dietzschold B., Kajiyama W., Fu Z.F., Koprowski H., Notkins A.L., Development of human monoclonal antibodies to rabies. Hybridoma, 1994, 13, 397-402.
37. 2 from plasma. J Chromatogr B Analyt Technol Biomed Life Sci, 2008, 876, 109-115.
38. Folb J.E., Cooke R.P., Issues of human rabies immunoglobulin and vaccine: policy versus practice. J Public Health (Oxf), 2007, 29, 83-87.
39. Gautret P., Soula G., Adamou H., Soavi M.J., Delmont J., Rotivel Y., Parola P., Brouqui P., Rabies postexposure prophylaxis, Marseille, France, 1994-2005. Emerg Infect Dis, 2008, 14, 1452-1454.
40. Glück R., Labert D., Techniques de purification de l'immunsérum antirabique hétérologue. La rage: techniques de laboratoire, Meslin F.-X, Kaplan M.M.,. Koprowski H (Eds.), 1999, Organisation Mondiale de la Santé, Genève, pp. 411-416.
41. Goudsmit J., Marissen W.E., Weldon W.C., Niezgoda M., Hanlon C.A., Rice A.B., Kruif J., Dietzschold B., Bakker A.B., Rupprecht C.E., Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis, 2006, 193, 796-801.
42. Habel K., Seroprophylaxis in experimental rabies. Pub Hlth Rep, 1945, 60, 545.
43. Hanlon C.A., Kuzmin I.V., Blanton J.D., Weldon W.C., Manangan J.S., Rupprecht C.E., Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res, 2005, 111, 44-54.
44. Hattwick M.A.W., Rubin R.H., Music S., Sikes R.K., Smith J.S., Gregg M. D., Postexposure rabies prophylaxis with human rabies immune globulin. J Am Med Assoc, 1974, 227, 407.
45. Helmick C.G., Johnstone C., Sumner J., Winkler W.G., Fager S., A clinical study of Merieux human rabies immune globulin. J Biol Stand, 1982, 10, 357-367.
46. Hosty T.S., Kissling R.E., Schaeffer M., Wallace G.A., Dibble E.H., Human antirabies gamma globulin. Bull World Health Organ, 1959, 20, 1111-1119.
47. Kaplan M.M., Cohen D., Koprowski H., Dean D., Ferrigan, L., Studies on the local treatment of wounds for the prevention of rabies. Bull World Health Organ, 1962, 26, 765-775.
48. Kaplan M.M., Paccaud M.F., Effectiveness of locally inoculated antirabies serum and gamma-globulin in rabies infection of mice. Bull World Health Organ, 1963, 28, 495-497.
49. Karliner J.S., Belaval G.S., Incidence of reactions following administration of antirabies serum; study of 526 cases. J Amer Med Assoc, 1965, 193, 359-362.
50. Knobel D.L., Cleaveland S., Coleman P.G., Fevre E.M., Meltzer M.I., Miranda M.E., Shaw A., Zinsstag J., Meslin F.X., Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ, 2005, 83, 360-368.
51. Koprowski H., Van der Scheer J., Black J., Use of hyperimmune antirabies serum concentrates in experimental animals. Am J Med, 1950, 8, 412.
52. Kuzmin I.V., Wu X., Tordo N., Rupprecht C.E., Complete genomes of Aravan, Khujand, Irkut and West Caucasian bat viruses, with special attention to the polymerase gene and non-coding regions. Virus Res, 2008,136, 81-90.
53. Lafon M., Edelman L., Bouvet J.P., Lafage M., Montchatre E., Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol, 1990, 71, 1689-1696.
54. Lang J., Attanath P., Quiambao B., Singhasivanon V., Chanthavanich P., Montalban C., Lutsch C., Pepin-Covatta S., Le Mener V., Miranda M., Sabchareon A., Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Trop, 1998, 70, 313-333.
55. Luekrajang T., Wangsai J., Phanuphak P., Production de sérum antirabique d'origine équine, La rage: techniques de laboratoire, Meslin F.-X., Kaplan M.M., Koprowski H. (Eds.), 1999, Organisation Mondiale de la Santé, Genève, pp. 407-410.
56. Marie A., Recherches sur le sérum antirabique. Ann Inst Pasteur (Paris), 1908, 22, 271.
57. Marissen W.E., Kramer R.A., Rice A., Weldon W.C., Niezgoda M., Faber M., Slootstra J.W., Meloen R.H., Clijsters-van der Horst M., Visser T.J., Jongeneelen M., Thijsse S., Throsby M., de Kruif J., Rupprecht C.E., Dietzschold B., Goudsmit J., Bakker A.B., Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol, 2005, 79, 4672-4678.
58. Muhamuda K., Madhusudana S.N., Ravi V., Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies. Hum Vaccin, 2007, 3, 192-195.
59. OMS, Comité d'expert de la rage. G. (Ed.), Série de rapports techniques. Deuxième rapport, Organisation Mondiale de la Santé, Genève, 1954.
60. Proca G., Bobes S., Immunisation contre la rage: vaccins vivants et vaccins tués. Bull Org Hyg SDN, 1940, 9, 85-137.
61. Prosniak M., Faber M., Hanlon C.A., Rupprecht C.E., Hooper D.C., Dietzschold B. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis, 2003,188, 53-56.
62. Quiambao B.P., Dytioco H.Z., Dizon R.M., Crisostomo M.E., Laot T.M., Teuwen D.E., Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab). PLoS Negl Trop Dis, 2008, 2, e243.
63. Saesow N., Chaiwatanarat T., Mitmoonpitak C., Wilde H., Diffusion and fate of intramuscularly injected human rabies immune globulin. Acta Trop, 2000, 76, 289-292.
64. Schumacher C.L., Dietzschold B., Ertl H.C., Niu H.S., Rupprecht C.E., Koprowski H., Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. J Clin Invest, 1989, 84, 971-975.
65. Schumacher C.L., Ertl H.C., Koprowski H., Dietzschold B., Inhibition of immune responses against rabies virus by monoclonal antibodies directed against rabies virus antigens. Vaccine, 1992, 10, 754-760.
66. Selimov M., Boltucij L., Semenova E., Kobrinskij G., Zmusko L., Results of the use of antirabies gamma glubulin and vaccine in prophylaxis of rabies in the Soviet Union. J Hyg Epidem Microbiol Immunol (Praha), 1959, 3, 168.
67. Sikes R.K., Human rabies immune globulin. Public Health Rep, 1969, 84, 797-801.
68. Sloan S.E., Hanlon C., Weldon W., Niezgoda M., Blanton J., Self J., Rowley K.J., Mandell R.B., Babcock G.J., Thomas W.D. Jr., Rupprecht C.E., Ambrosino D.M., Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine, 2007, 25, 2800-2810.
69. Suwansrinon, K., Jaijareonsup W., Wilde H., Benjavongkulchai M., Sriaroon C., Sitprija V., Sex- and age-related differences in rabies immunoglobulin hypersensitivity. Trans R Soc Trop Med Hyg, 2007, 101, 206-208.
70. Suwansrinon K., Jaijaroensup W., Daviratanasilpa S., Sriaroon C., Wilde H., Sitprija V. Adverse reactions to human rabies immune globulin manufactured by the Thai Red Cross Society. Vaccine, 2005, 23, 1324-1325.
71. WHO, Comité d'experts de la rage, G. (Ed.), Série de rapports techniques. Premier rapport, Organisation Mondiale de la Santé, Genève, 1950.
72. WHO, Who Expert Committee on Rabies, G. (Ed.) Who Technical Report Series. Sixth Report, World Health Organization, Genève, 1973.
73. WHO, Rabies vaccine. Position paper. Wkly Epidemiol Rec, 2007, 425-435.
74. Wiktor T.J., Lerner R.A., Koprowski H., Inhibitory effect of passive antibody on active immunity induced against rabies by vaccination. Bull World Health Organ, 1971, 45, 747-753.
75. Wilde H., Failures of post-exposure rabies prophylaxis. Vaccine, 2007, 25, 7605-7609.
76. Willoughby R.E. Jr., Tieves K.S., Hoffman G.M., Ghanayem N.S., Amlie-Lefond C.M., Schwabe M.J., Chusid M.J., Rupprecht C.E., Survival after treatment of rabies with induction of coma. N Engl J Med, 2005, 352, 2508-2514.
77. Winkler W.G., Schmidt R.C., Sikes R.K. Evaluation of human rabies immune globulin and homologous and heterologous antibody. J Immunol, 1969, 102, 1314-1321.
78. Zhao X.L., Yin J., Chen W.Q., Jiang M., Yang G., Yang Z.H., Generation and characterization of human monoclonal antibodies to G5, a linear neutralization epitope on glycoprotein of rabies virus, by phage display technology. Microbiol Immunol, 2008, 52, 89-93.